Percheron Therapeutics Limited (ASX: PER) is an international biotechnology company focused on the development of novel therapies for rare diseases.
The company’s lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The drug has previously reported promising results from an exploratory phase IIa study in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.
For more information, please contact info@PercheronTx.com.
Company Details
- Employees
- 9
- Founded
- -
- Address
- L30, 35 Collins Street, Melbourne,victoria 3000,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- antisense.com.au
- Keywords
- Recce Pharmaceuticals Ltd.
- HQ
- Melbourne, Victoria
Percheron Therapeutics Limited Questions
Percheron Therapeutics Limited's website is antisense.com.au
Percheron Therapeutics Limited's LinkedIn profile is https://au.linkedin.com/company/percherontx
Percheron Therapeutics Limited has
9 employees.
View email and phone details for 9
employees at Percheron Therapeutics Limited.
Percheron Therapeutics Limited's industry is
Biotechnology Research
Percheron Therapeutics Limited's top competitors are
Recce Pharmaceuticals Ltd,
Neuren Pharmaceuticals Limited,
Paras And Partners Executive Search And Selection,
Percheron, Llc,
Kazia Therapeutics Limited,
Telix Pharmaceuticals Limited,
Hummingbird Bioscience,
Australian Stroke Alliance,
Cormagna,
Aft Pharmaceuticals.
Percheron Therapeutics Limited's categories are Biotechnology Research
Percheron Therapeutics Limited's founding year is 2000
